SOX13 is a SRY-box transcription factor that binds DNA at consensus sequences and regulates diverse developmental and pathological processes. The protein functions as a transcriptional repressor of myelin-associated genes and modulates Wnt signaling by inhibiting TCF7/TCF1 activity, thereby controlling oligodendroglia differentiation and T-cell specification 1. SOX13 promotes brown adipocyte differentiation and gamma-delta T-cell development, including IL-17A-expressing populations 1. Recent evidence suggests SOX13 plays dual roles in cancer: in hepatocellular carcinoma and colorectal cancer, elevated SOX13 promotes metastasis by transactivating EMT-related genes Twist1 and SNAI2, and the c-MET pathway 23. Conversely, in gastric cancer, SOX13 promotes ferroptosis resistance by upregulating mitochondrial respiratory chain assembly; zanamivir targets SOX13 to restore ferroptosis sensitivity 4. In breast cancer, high SOX13 independently predicts poor overall survival and correlates with immune suppression 5. Emerging evidence links SOX13 to neurodevelopment through POU3F2-mediated regulation of canonical Wnt signaling in neural progenitors 6, and de novo truncating variants in SOX13 are candidate causes of congenital kidney and urinary tract anomalies 7. The c-MET inhibitor crizotinib can block SOX13-driven colorectal cancer progression by disrupting the HGF/STAT3/SOX13/c-MET axis.